0001209191-23-001019.txt : 20230104
0001209191-23-001019.hdr.sgml : 20230104
20230104165102
ACCESSION NUMBER: 0001209191-23-001019
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221230
FILED AS OF DATE: 20230104
DATE AS OF CHANGE: 20230104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nagendran Sukumar
CENTRAL INDEX KEY: 0001665124
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 23507390
MAIL ADDRESS:
STREET 1: C/O AVEXIS, INC., 2275 HALF DAY ROAD
STREET 2: SUITE 160
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-30
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001665124
Nagendran Sukumar
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, SUITE 1430
DALLAS
TX
75247
1
1
0
0
President and Head of R&D
Stock Option (right to buy)
2.26
2022-12-30
4
A
0
790093
0.00
A
2032-12-30
Common Stock
790093
790093
D
25% of the total number of shares underlying the option shall vest and become exercisable on December 16, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ Kamran Alam, Attorney-in-Fact
2023-01-04